SCHEMBL17407201

SCHEMBL17407201

Cc1c(Cl)cc(-c2csc(N)n2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
LTA4H P09960 4/20 0.47
MAPT P10636 8/20 0.46
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 5/20 0.46
KDM4E B2RXH2 3/20 0.46
NFKB1 P19838 2/20 0.46
GFER P55789 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
AR P10275 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
HSD17B10 Q99714 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17407198 0.89 ALDH1A1 (0.51) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL27916623 0.81 ALDH1A1 (0.48) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL3140677 0.81 ALDH1A1 (0.52) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL17400558 0.81 ALDH1A1 (0.54) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL476082 0.79 LTA4H (0.56) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL6973568 0.79 ALDH1A1 (0.53) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL27985361 0.79 LTA4H (0.54) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL474314 0.78 RAB9A (0.59) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL17407200 0.78 ALDH1A1 (0.58) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2
SCHEMBL29654117 0.77 ALDH1A1 (0.44) ALDH1A1LTA4HMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 US disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 US disclosed
US-9562044-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-02-07 US disclosed
US-20160002218-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002218-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, CHRM5 ALDH1A1 1565/4885LTA4H 944/4885MAPT 700/4885
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 ALDH1A1 1551/4885LTA4H 1000/4885MAPT 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.